ReviewInfectious diseases and therapy2022
Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.
Review in Infectious diseases and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Effectiveness of carbon dioxide cryotherapy for the treatment of cutaneous leishmaniasis: Systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Treatment outcomes of cutaneous leishmaniasis due to Leishmania aethiopica: A systematic review and meta-analysis.PloS one · 2023Pooled it
- A phase Ib/II clinical study to evaluate the safety and efficacy of topical Arnica tincture to treat non-complicated cutaneous leishmaniasis in Colombia.PLoS neglected tropical diseases · 2025Trial
- Antileishmanial activity of gold(I) compounds containing triphenylphosphine ligands against Leishmania amazonensis: impacts on mitochondrial bioenergetics and trypanothione reductase activity.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Survival Analysis in Cutaneous Leishmaniasis Patients: A Retrospective Cohort Study.Biomedicines · 2026Article
- Article
- A 10-year registry-based retrospective study of cutaneous Leishmaniasis in Mashhad, northeastern Iran: Demographic, clinical, and therapeutic profiles of 1537 cases.Parasite epidemiology and control · 2026Article
- Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases.Drug delivery and translational research · 2026Review
- Immunotherapeutic potential of PD-1 blockade in chronic Leishmania mexicana infection through the enhancement of progenitor-like CXCR5Frontiers in immunology · 2026Article
- Article
- In Vitro Assessment of the Combined Activity of Amphotericin B and CuTropical medicine and infectious disease · 2025Article
- Genetic variation of cutaneous leishmaniasis causative species in Ethiopia.Scientific reports · 2025Article
- Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment.Biomedicines · 2025Review
- The Safety and Efficacy of an Immunomodulator Garlic-Based Cream (LeishG1) for Treating Uncomplicated Cutaneous Leishmaniasis: A Single-Blind, Multi-Center Study.Health science reports · 2025Article
- Global burden of leishmaniasis, 1990-2021: systematic analysis of the global burden of disease study.International journal for equity in health · 2025Article
- Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to Vaccine Strategies for Disease Control.Acta parasitologica · 2025Review
- Evaluation of Cutaneous Leishmaniasis Cases in the Southeastern Border of Turkey in Recent Years.Iranian journal of public health · 2025Article
- Structural Drivers of Cutaneous Leishmaniasis: Examining How the Converging Effects of Displacement, Environmental Disruption, and Political Instability Reshape Epidemiology Beyond Endemic Regions.Tropical medicine and infectious disease · 2025Review
- Rapidly Progressive Cutaneous Leishmaniasis in a Patient With HIV and Type 2 Diabetes Mellitus: A Case Report.Cureus · 2025Article
- Successful treatment of meglumine antimoniate in patient with cutaneous leishmaniasis with end-stage renal failure undergoing hemodialysis: a case report.Journal of medical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cutaneous leishmaniasis (CL) is a complex skin infection that has imposed a heavy burden on many developing countries and is caused by more than 20 Leishmania species. This disease is predominantly associated with disfiguring scars and major social stigma upon infection. The severity of the disease seemingly depends on many factors including the species of parasite, the host, region of endemicity, socio-economic status and the accessibility to health facilities. Despite myriad studies that have been performed on current and novel therapies, the treatment outcomes of CL remain contentious, possibly because of the knowledge gaps that still exist. The differential responses to the current CL therapies have become a major drawback in disease control, and the dearth of information on critical analyses of outcomes of such studies is a hindrance to the overall understanding. On the basis of currently available literature on treatment outcomes, we discuss the most effective doses, drug susceptibilities/resistance and treatment failures of the Leishmania genus for both monotherapy and combination therapy. This review focuses on the available treatment modalities for CL caused by different Leishmania species, with insights into their species-specific efficacies, which would inform the selection of appropriate drugs for the treatment and control of leishmaniasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.